L

Lalnunkima

Active Director Director DIN 10803948
DIN 10803948 First appointment Feb 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Feb 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Lalnunkima

Data last updated:

Lalnunkima is a Director at Lamont Laboratories Private Limited (since 2025) and Director at Lamont Pharmaceutical Private Limited (since 2025). The companies operate in Paper.

DIN 10803948
Primary Designation Director
Industry Paper
First Appointment 07 Feb 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Lamont Laboratories Private Limited U21002BR2025PTC080004
Director07 Nov 20252025Active
Director07 Feb 20252025Active

Board colleagues of Lalnunkima

Directorship timeline

Open interactive timeline →
Lamont Laboratories Private Limited
Lamont Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Lalnunkima

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lalnunkima

Lalnunkima currently holds 2 directorships: Lamont Laboratories Private Limited (Director, since 07 Nov 2025); Lamont Pharmaceutical Private Limited (Director, since 07 Feb 2025).

Lalnunkima was first appointed on 07 Feb 2025 as Director at Lamont Pharmaceutical Private Limited.

The current boards of Lalnunkima's companies include Niraj Kumar (Lamont Laboratories Private Limited), Soni Sharma (Lamont Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available